Physician profile
Peter Joseph Murphy
NPI 1437191657
$4,476.65
in general payments reported to CMS, 2019-2025
16 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,946 · 2020: $184 · 2022: $25.55 · 2023: $101 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $3,303.98 | 2019 | |
| Edwards Lifesciences Corporation | $183.95 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $168.19 | 2019-2025 | Uptravi, Opsumit |
| La Jolla Pharmaceutical Company | $165.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.21 | 2019-2023 | Ofev |
| Genentech USA, INC. | $139.43 | 2019 | |
| Amgen INC. | $98.08 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $70.41 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $44.69 | 2019 | |
| Allergan, INC. | $37.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.64 | 2019 | |
| Merck Sharp & Dohme LLC | $18.71 | 2019 | |
| Pfizer INC. | $17.82 | 2019 | |
| Mylan Specialty L.P. | $17.61 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.